全体要約
製品別に見ると、細胞治療セグメントが再生医療市場の中で支配的なシェアを占めています。また、2022年の治療領域では、運動器疾患のセグメントが最大のシェアを持ち、整形外科疾患の増加と再生研究への関心の高まりが影響しています。地域別では、アジア太平洋（APAC）地域が急成長することが期待されており、慢性疾患の高い負担、所得の増加、新技術への需要が市場成長を後押ししています。
関連する質問
49.0 Billion USD (2028)
25.1% (2023 to 2028)
Novartis AG, Biogen, Inc., Sarepta Therapeutics, Inc., Gilead Sciences, Inc., Amgen Inc., Smith+Nephew, MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Company Limited, CORESTEM, Inc., Vericel Corporation, MIMEDX Group, Inc., Organogenesis Inc., Medtronic, Bristol-Myers Squibb Company, Orthocell Ltd., Mesoblast Ltd., BioRestorative Therapies, Inc., Pluristem Therapeutics Inc., TEGOSCIENCE, ANTEROGEN.CO.,LTD., Bluebird bio, Inc., Stempeutics Research Pvt Ltd., Sibiono GeneTech Co. Ltd., Aspect Biosystems Ltd., Athersys, Inc.
パーソナライズドメディスンへの集中の高まり, 再生医療における規制承認の急増, 主要市場プレイヤーによる協力とパートナーシップの増加
概要
「細胞療法セグメントは再生医療市場で支配的なシェアを占めていました。」
製品別に、世界の再生医療市場は遺伝子治療、細胞治療（幹細胞治療【細胞移植、幹細胞治療製品{自家療法、同種療法}、細胞ベースの免疫療法製品）、および組織工学製品に分かれています。幹細胞治療の人気が高まることにより、細胞治療市場の拡大が期待されています。
「筋骨格障害セグメントは、2022年の治療領域セグメントで最大のシェアを占めました。」
治療分野に基づいて、再生医療市場は腫瘍学、筋骨格障害、神経学、眼科学、皮膚科および創傷管理、心血管疾患、その他の応用にセグメント化されています。これは、整形外科疾患の有病率の増加と筋骨格再生研究への関心の高まりに起因しています。
「APAC地域はより速いペースで成長する可能性があります。」
再生医療市場は、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカに分かれています。アジア太平洋地域は、予測期間中に重要なCAGRで成長することが予想されています。慢性疾患の高い負担、一人当たりの所得の増加、新しい技術への需要の高まりが、この地域の再生医療市場の成長を支えると予想されています。
このレポートのために実施された主なインタビューは、以下のように分類されます：
• 参画者別：供給側 - 80%、需要側 - 20%
• 役職別（供給側）：マネージャー - 45%、CXOとディレクター - 30%、エグゼクティブ - 25%
地域別：北アメリカ -55%、ヨーロッパ -10%、アジア太平洋 -20%、ラテンアメリカ -10%、中東・アフリカ -5%
レポートに掲載されている企業のプロフィール一覧：
・ノバルティス社（スイス）
バイオジェン社 (米国)
サレプタ・セラピューティクス社（アメリカ）
• ギリアド・サイエンシズ社 (米国)
・アムジェン社（米国）
スミス+ネフュー（イギリス）
・MEDIPOST株式会社（韓国）
・JCRファーマ株式会社（日本）
武田薬品工業株式会社（日本）
・コアステム株式会社（韓国）
・ベリセル・コーポレーション（米国）
• MIMEDXグループ株式会社（アメリカ）
オルガノジェネシス株式会社 (米国)
メドトロニック（アイルランド）
・ブリストル・マイヤーズ スクイブ社（米国）
オルソセル社（オーストラリア）
メソブラスト社（オーストラリア）
バイオリストラティブセラピー株式会社（アメリカ）
プルリステム・セラピューティクス社（アメリカ）
• テゴサイエンス（韓国）
アンテロゲン株式会社（韓国）
・ブルーバードバイオ社（アメリカ）
• ステンペューティクスリサーチプライベートリミテッド（インド）
シビオノ・ジェンテック株式会社（中国）
・アスペクトバイオシステムズ株式会社（カナダ）
アサースィス社（アメリカ）
調査対象:
このレポートは、再生医療市場の詳細な状況を提供します。市場の規模や将来の成長可能性を、製品、治療領域、地域などの異なるセグメントにわたって推定することを目的としています。また、主要な市場プレーヤーの詳細な競争分析や、彼らの企業プロフィール、最近の動向、主要な市場戦略も含まれています。
レポート購入の主な利点：
この報告書は、市場のリーダーや新規参入者に、再生医療市場全体とそのサブセグメントの収益数値に最も近い推定値を提供することで支援します。また、利害関係者が競争環境をよりよく理解し、ビジネスをより適切に位置付け、適切な市場戦略を立てるための洞察を得るのにも役立ちます。この報告書は、利害関係者が市場の動向を理解し、主要な市場の推進要因、抑制要因、機会、および課題に関する情報を提供します。
レポートは以下のポイントに関する洞察を提供します:
再生医療市場の成長に影響を与えている主な要因（個別化医療への注目の高まり、再生医療における規制承認の急増、大手市場プレーヤーによるコラボレーションとパートナーシップの増加、新しい治療領域における範囲の拡大）、抑制要因（長期データの不足、倫理的および法的問題、高額な治療費）、機会（人工知能およびビッグデータとの統合、3D印刷の可能性の活用、増加する臓器移植数）、および課題（さまざまな地域での好ましい償還政策の不足）が影響を与えています。
・製品開発/イノベーション：再生医療市場における新しく発売された製品に関する詳細な洞察。
市場開発：利益のある市場に関する包括的な情報 - この報告書は、さまざまな地域にわたる再生医療市場を分析しています。
市場の多様化：再生医療市場における新製品、未開拓の地域、最近の開発、投資に関する詳細な情報。
• 競争評価：市場シェア、成長戦略、主要プレーヤーの製品提供に関する詳細な評価には、ノバルティスAG（スイス）、バイオジェン（アメリカ）、サレプタ・セラピューティクス（アメリカ）、ギリアド・サイエンシズ（アメリカ）、アムジェン（アメリカ）、スミス・アンド・ネフュー（イギリス）、MEDIPOST（韓国）、JCRファーマ（日本）、武田薬品工業（日本）、CORESTEM（韓国）などが含まれます。再生医療市場において。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 イントロダクション 35
1.1 調査の目的 35
1.2 市場の定義 35
1.2.1 包含・除外事項 36
1.3 市場範囲 36
1.3.1 対象市場 36
1.3.2 対象年 37
1.3.3 通貨 37
1.4 調査上の制約 37
1.5 ステークホルダー 38
1.6 変化のサマリー 38
1.7 再生医療市場におけるリセッションのインパクト 39
2 調査手法 40
2.1 リサーチデータ 40
2.1.1 二次データ 41
2.1.2 一次データ 42
2.2 市場規模予測 43
2.2.1 プライマリー考察 47
2.2.2 セグメント評価の方法論：再生医療市場 47
2.3 市場内訳・データのトライアンギュレーション 50
2.4 調査の前提 51
2.5 リスク分析 51
2.6 再生医療市場におけるリセッションのインパクト 52
3 エグゼクティブサマリー 54
4 更なる考察 57
4.1 再生医療市場の概要 57
4.2 北米：再生医療市場 58
4.3 再生医療市場、地理的側面での成長機会 59
5 市場概要 60
5.1 イントロダクション 60
5.2 市場ダイナミクス 60
5.2.1 促進要因 61
- 5.2.1.1 個別化医療への注目の高まり 61
- 5.2.1.2 新しい治療領域における新たなアプリケーション 62
- 5.2.1.3 主要市場プレーヤーによる協力とパートナーシップの増加 64
- 5.2.1.4 再生医療における認可の増加 65
5.2.2 抑制要因 66
- 5.2.2.1 長期データの欠如 66
- 5.2.2.2 倫理的・法的懸念と高額な治療費 66
5.2.3 市場機会 67
- 5.2.3.1 3Dプリンティングの可能性を活用 67
- 5.2.3.2 人工知能やビッグデータとの統合 68
- 5.2.3.3 増加する臓器移植 68
5.2.4 課題 69
- 5.2.4.1 さまざまな地域で有利な償還政策が欠如している 69
5.3 顧客事業にインパクトのあるトレンド/ディスラプション 70
5.4 価格分析 71
5.4.1 主要プレイヤーの平均販売価格トレンド、製品別 71
5.5 サプライチェーン分析 72
5.6 バリューチェーン分析 73
5.7 エコシステム分析 74
5.8 技術分析 76
5.9 特許分析 78
5.10 2024-2025年の主な会議とイベント 81
5.10.1 2024-2025年の再生医療学会 81
5.11 関税と規制の状況 82
5.11.1 FDAの承認 82
5.11.2 規制当局、政府機関、その他組織 83
5.12 ポーターのファイブフォース分析 87
5.12.1 新規参入の脅威 87
5.12.2 代替品の脅威 87
5.12.3 買い手の交渉力 88
5.12.4 サプライヤーの交渉力 88
5.12.5 競争の激しさ 88
5.13 主なステークホルダーと購入基準 89
5.13.1 購買プロセスにおける主要ステークホルダー 89
5.13.2 再生医療製品の購入基準 89
5.14 パイプライン分析 90
6 再生医療の市場、製品別 94
6.1 イントロダクション 95
6.2 細胞療法 95
6.2.1 幹細胞治療 98
- 6.2.1.1 細胞移植 101
- 6.2.1.1.1 AML治療におけるAllo-SCTの可能性がセグメント成長を牽引 101
- 6.2.1.2 幹細胞治療製品 104
- 6.2.1.2.1 自家療法 107
- 6.2.1.2.2 同種療法 110
- 6.2.1.1 細胞移植 101
6.2.2 細胞ベースの免疫療法 113
6.3 遺伝子治療 116
6.4 組織工学 119
7 再生医療の市場、治療エリア別 123
7.1 イントロダクション 124
7.2 オンコロジー 125
7.2.1 幹細胞移植の増加が市場を牽引 125
7.3 筋骨格系疾患 130
7.4 皮膚科・創傷治療 133
7.4.1 創傷治療用生物製剤の使用増加が市場を牽引 133
7.5 循環器系疾患 136
7.6 眼科 139
7.6.1 AMDの眼組織再生が市場成長を支える 139
7.7 神経学 143
7.8 その他治療エリア 146
8 再生医療の市場、地域別 150
8.1 イントロダクション 151
8.2 北米 152
8.2.1 米国 156
8.2.2 カナダ 159
- 8.2.2.1 再生医療研究に対する政府のイニシアチブの高まりが市場を牽引 159
8.2.3 北米：リセッション時のインパクト 162
8.3 ヨーロッパ 163
8.3.1 ドイツ 166
8.3.2 英国 168
8.3.3 フランス 171
- 8.3.3.1 再生医療製品パイプラインを推進する構造化された規制の枠組み 171
8.3.4 イタリア 173
- 8.3.4.1 神経疾患と心血管疾患の有病率の上昇が市場を牽引 173
8.3.5 スペイン 176
- 8.3.5.1 製品パイプラインを促進する良好な規制環境 176
8.3.6 その他のヨーロッパ 179
8.3.7 ヨーロッパ：リセッション時のインパクト 182
8.4 アジア太平洋 182
8.4.1 中国 186
8.4.2 日本 189
- 8.4.2.1 治療法の商業化を推進するための薬事法の規制改正 189
8.4.3 インド 192
8.4.4 韓国 194
8.4.5 オーストラリア 197
- 8.4.5.1 スポーツ障害の増加が市場成長を支える 197
8.4.6 その他のアジア太平洋 199
8.4.7 アジア太平洋：リセッション時のインパクト 201
8.5 ラテンアメリカ 202
8.5.1 ブラジル 204
- 8.5.1.1 市場成長を支える医薬品研究開発の漸進的増加 204
8.5.2 その他のラテンアメリカ 206
8.5.3 ラテンアメリカ：リセッション時のインパクト 209
8.6 中東 210
8.7 アフリカ 213
8.7.1 今後の成長を支える協力関係の拡大 213
8.7.2 アフリカ：リセッション時のインパクト 215
9 競合情勢 216
9.1 イントロダクション 216
9.2 主要プレーヤーが採用するRight-to-Winアプローチ 216
9.3 REVENUE SHARE ANALYSIS 219
9.4 市場シェア分析 219
9.5 企業評価マトリックス 221
9.5.1 STARS 222
9.5.2 EMERGING LEADERS 222
9.5.3 PERVASIVE PLAYERS 222
9.5.4 PARTICIPANTS 222
9.5.5 企業フットプリント分析 224
9.6 スタートアップ/中小企業評価マトリックス 226
9.6.1 PROGRESSIVE COMPANIES 226
9.6.2 RESPONSIVE COMPANIES 226
9.6.3 DYNAMIC COMPANIES 226
9.6.4 STARTING BLOCKS 226
9.6.5 競合ベンチマーキング 228
9.7 COMPETITIVE SCENARIO & TRENDS 230
9.7.1 製品展開 230
9.7.2 ディール 233
9.7.3 その他の展開 237
10 企業プロファイル 239
10.1 主要市場プレイヤー 239
10.1.1 NovartisAG 239
10.1.2 バイオジェン社 244
10.1.3 ギリアド・サイエンシズ 248
10.1.4 サレプタ・セラピューティクス社 253
10.1.5 アムジェン社 256
10.1.6 スミス＋ネフュー 259
10.1.7 株式会社メディポスト 262
10.1.8 JCR製薬株式会社 265
10.1.9 武田薬品工業 267
10.1.10 コアステム社 270
10.1.11 株式会社ベリセル 272
10.1.12 ミメデックス・グループ 274
10.1.13 オルガノジェネシス社 278
10.1.14 メドトロニック 281
10.1.15 ブリストルマイヤーズスクイブ 284
10.2 他の有力企業 288
10.2.1 ORTHOCELL LTD 288
10.2.2 MESOBLAST LTD 289
10.2.3 BIORESTORATIVE THERAPIES, INC 290
10.2.4 PLURISTEM THERAPEUTICS INC 290
10.2.5 TEGOSCIENCE 291
10.2.6 ANTEROGEN.CO.,LTD 292
10.2.7 BLUEBIRD BIO, INC 293
10.2.8 STEMPEUTICS RESEARCH PVT. LTD 294
10.2.9 SIBIONO GENETECH CO. LTD 294
10.2.10 ASPECT BIOSYSTEMS 295
11 付録 297
11.1 ディスカッションガイド 297
11.2 ナレッジストア 300
11.3 カスタマイズオプション 302
11.4 関連レポート 302
11.5 執筆者の詳細 303
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
Table of Contents
1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.3 MARKET SCOPE 36
1.3.1 MARKETS COVERED 36
1.3.2 YEARS CONSIDERED 37
1.3.3 CURRENCY CONSIDERED 37
1.4 RESEARCH LIMITATIONS 37
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 38
1.7 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY DATA 42
2.2 MARKET SIZE ESTIMATION 43
2.2.1 PRIMARY INSIGHTS 47
2.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET 47
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 50
2.4 STUDY ASSUMPTIONS 51
2.5 RISK ANALYSIS 51
2.6 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET 52
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 57
4.1 REGENERATIVE MEDICINE MARKET OVERVIEW 57
4.2 NORTH AMERICA: REGENERATIVE MEDICINE MARKET 58
4.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
- 5.2.1.1 Growing focus on personalized medicine 61
- 5.2.1.2 Emerging applications in new therapeutic areas 62
- 5.2.1.3 Increasing collaborations and partnerships by major market players 64
- 5.2.1.4 Increasing regulatory approvals in regenerative medicine 65
5.2.2 RESTRAINTS 66
- 5.2.2.1 Lack of long-term data 66
- 5.2.2.2 Ethical and legal concerns and high cost of treatments 66
5.2.3 OPPORTUNITIES 67
- 5.2.3.1 Harnessing the potential of 3D printing 67
- 5.2.3.2 Integration with artificial intelligence and big data 68
- 5.2.3.3 Growing number of organ transplants 68
5.2.4 CHALLENGES 69
- 5.2.4.1 Lack of favorable reimbursement policies across various regions 69
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 70
5.4 PRICING ANALYSIS 71
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 71
5.5 SUPPLY CHAIN ANALYSIS 72
5.6 VALUE CHAIN ANALYSIS 73
5.7 ECOSYSTEM ANALYSIS 74
5.8 TECHNOLOGY ANALYSIS 76
5.9 PATENT ANALYSIS 78
5.10 KEY CONFERENCES & EVENTS IN 2024-2025 81
5.10.1 REGENERATIVE MEDICINE CONFERENCES IN 2024-2025 81
5.11 TARIFF & REGULATORY LANDSCAPE 82
5.11.1 FDA APPROVALS 82
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
5.12 PORTER’S FIVE FORCES ANALYSIS 87
5.12.1 THREAT OF NEW ENTRANTS 87
5.12.2 THREAT OF SUBSTITUTES 87
5.12.3 BARGAINING POWER OF BUYERS 88
5.12.4 BARGAINING POWER OF SUPPLIERS 88
5.12.5 DEGREE OF COMPETITION 88
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 89
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 89
5.13.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS 89
5.14 PIPELINE ANALYSIS 90
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
6.2 CELL THERAPY 95
6.2.1 STEM CELL THERAPY 98
- 6.2.1.1 Cell transplantations 101
- 6.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth 101
- 6.2.1.2 Stem cell therapy products 104
- 6.2.1.2.1 Autologous therapy 107
- 6.2.1.2.1.1 Low risk of post-treatment complications to support segment growth 107
- 6.2.1.2.2 Allogeneic therapy 110
- 6.2.1.2.2.1 High potential in disease treatment to ensure demand and development 110
- 6.2.1.2.1 Autologous therapy 107
- 6.2.1.1 Cell transplantations 101
6.2.2 CELL-BASED IMMUNOTHERAPY 113
- 6.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth 113
6.3 GENE THERAPY 116
6.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET 116
6.4 TISSUE ENGINEERING 119
6.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET 119
7 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA 123
7.1 INTRODUCTION 124
7.2 ONCOLOGY 125
7.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET 125
7.3 MUSCULOSKELETAL DISORDERS 130
7.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET 130
7.4 DERMATOLOGY & WOUND CARE 133
7.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET 133
7.5 CARDIOVASCULAR DISEASES 136
7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH 136
7.6 OPHTHALMOLOGY 139
7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH 139
7.7 NEUROLOGY 143
7.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH 143
7.8 OTHER THERAPEUTIC AREAS 146
8 REGENERATIVE MEDICINE MARKET, BY REGION 150
8.1 INTRODUCTION 151
8.2 NORTH AMERICA 152
8.2.1 US 156
- 8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market 156
8.2.2 CANADA 159
- 8.2.2.1 Rising government initiatives for regenerative medicine research to drive market 159
8.2.3 NORTH AMERICA: RECESSION IMPACT 162
8.3 EUROPE 163
8.3.1 GERMANY 166
- 8.3.1.1 Rising focus on clinical research and patent approvals to drive market 166
8.3.2 UK 168
- 8.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market 168
8.3.3 FRANCE 171
- 8.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline 171
8.3.4 ITALY 173
- 8.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market 173
8.3.5 SPAIN 176
- 8.3.5.1 Favorable regulatory environment to drive product pipeline 176
8.3.6 REST OF EUROPE 179
8.3.7 EUROPE: RECESSION IMPACT 182
8.4 ASIA PACIFIC 182
8.4.1 CHINA 186
- 8.4.1.1 Favorable government support for development of regenerative medicine to drive market 186
8.4.2 JAPAN 189
- 8.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies 189
8.4.3 INDIA 192
- 8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth 192
8.4.4 SOUTH KOREA 194
- 8.4.4.1 Strong research base and availability of funds to support market growth 194
8.4.5 AUSTRALIA 197
- 8.4.5.1 Increasing incidence of sports injuries to support market growth 197
8.4.6 REST OF ASIA PACIFIC 199
8.4.7 ASIA PACIFIC: RECESSION IMPACT 201
8.5 LATIN AMERICA 202
8.5.1 BRAZIL 204
- 8.5.1.1 Gradual increase in pharmaceutical R&D to support market growth 204
8.5.2 REST OF LATIN AMERICA 206
8.5.3 LATIN AMERICA: RECESSION IMPACT 209
8.6 MIDDLE EAST 210
8.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS 210
8.6.2 MIDDLE EAST: RECESSION IMPACT 212
8.7 AFRICA 213
8.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS 213
8.7.2 AFRICA: RECESSION IMPACT 215
9 COMPETITIVE LANDSCAPE 216
9.1 INTRODUCTION 216
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 216
9.3 REVENUE SHARE ANALYSIS 219
9.4 MARKET SHARE ANALYSIS 219
9.5 COMPANY EVALUATION MATRIX 221
9.5.1 STARS 222
9.5.2 EMERGING LEADERS 222
9.5.3 PERVASIVE PLAYERS 222
9.5.4 PARTICIPANTS 222
9.5.5 COMPANY FOOTPRINT ANALYSIS 224
9.6 START-UP/SME EVALUATION MATRIX 226
9.6.1 PROGRESSIVE COMPANIES 226
9.6.2 RESPONSIVE COMPANIES 226
9.6.3 DYNAMIC COMPANIES 226
9.6.4 STARTING BLOCKS 226
9.6.5 COMPETITIVE BENCHMARKING 228
9.7 COMPETITIVE SCENARIO & TRENDS 230
9.7.1 PRODUCT LAUNCHES 230
9.7.2 DEALS 233
9.7.3 OTHER DEVELOPMENTS 237
10 COMPANY PROFILES 239
10.1 KEY MARKET PLAYERS 239
10.1.1 NOVARTIS AG 239
10.1.2 BIOGEN INC 244
10.1.3 GILEAD SCIENCES, INC 248
10.1.4 SAREPTA THERAPEUTICS, INC 253
10.1.5 AMGEN, INC 256
10.1.6 SMITH+NEPHEW 259
10.1.7 MEDIPOST CO., LTD 262
10.1.8 JCR PHARMACEUTICALS CO., LTD 265
10.1.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 267
10.1.10 CORESTEM, INC 270
10.1.11 VERICEL CORPORATION 272
10.1.12 MIMEDX GROUP, INC 274
10.1.13 ORGANOGENESIS INC 278
10.1.14 MEDTRONIC 281
10.1.15 BRISTOL-MYERS SQUIBB COMPANY 284
10.2 OTHER PLAYERS 288
10.2.1 ORTHOCELL LTD 288
10.2.2 MESOBLAST LTD 289
10.2.3 BIORESTORATIVE THERAPIES, INC 290
10.2.4 PLURISTEM THERAPEUTICS INC 290
10.2.5 TEGOSCIENCE 291
10.2.6 ANTEROGEN.CO.,LTD 292
10.2.7 BLUEBIRD BIO, INC 293
10.2.8 STEMPEUTICS RESEARCH PVT. LTD 294
10.2.9 SIBIONO GENETECH CO. LTD 294
10.2.10 ASPECT BIOSYSTEMS 295
11 APPENDIX 297
11.1 DISCUSSION GUIDE 297
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 300
11.3 CUSTOMIZATION OPTIONS 302
11.4 RELATED REPORTS 302
11.5 AUTHOR DETAILS 303
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024-2028 (% GROWTH) TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION) TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION) TABLE 4 REGENERATIVE MEDICINE MARKET: EMERGING APPLICATIONS TABLE 5 LIST OF KEY PRODUCT APPROVALS IN REGENERATIVE MEDICINE MARKET, 2021-2023 TABLE 6 REGENERATIVE MEDICINE PRICE TREND TABLE 7 ROLE IN ECOSYSTEM TABLE 8 STEM CELL THERAPIES AND GENE THERAPIES TABLE 9 REGENERATIVE MEDICINE MARKET: INDICATIVE LIST OF PATENTS TABLE 10 REGENERATIVE MEDICINE CONFERENCES IN 2024-2025 TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 15 REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS TABLE 16 GENE THERAPY PRODUCTS UNDER CLINICAL TRIAL TABLE 17 CELL THERAPY PRODUCTS UNDER CLINICAL TRIAL TABLE 18 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 20 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2021-2028 (USD MILLION) TABLE 21 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 22 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 24 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 26 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2021-2028 (USD MILLION) TABLE 27 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 28 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 30 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 31 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2021-2028 (USD MILLION) TABLE 32 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 33 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 34 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 35 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 37 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2021-2028 (USD MILLION) TABLE 38 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 39 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 40 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 41 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 42 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2021-2028 (USD MILLION) TABLE 43 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 44 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 45 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 46 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 47 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2021-2028 (USD MILLION) TABLE 48 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 49 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 50 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 51 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 52 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2021-2028 (USD MILLION) TABLE 53 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 55 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 56 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 57 APPROVED GENE THERAPIES, 2022 TABLE 58 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2021-2028 (USD MILLION) TABLE 59 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 60 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 61 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 62 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 63 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2021-2028 (USD MILLION) TABLE 64 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 65 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 66 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 67 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 68 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY THERAPEUTIC AREA, 2021 VS. 2022 TABLE 69 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 70 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS TABLE 71 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION) TABLE 72 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 73 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 74 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 75 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 76 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021-2028 (USD MILLION) TABLE 77 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 78 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 79 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 80 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 81 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS TABLE 82 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021-2028 (USD MILLION) TABLE 83 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 84 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 85 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 86 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 87 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION) TABLE 88 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 89 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 90 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 91 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 92 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY TABLE 93 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2021-2028 (USD MILLION) TABLE 94 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 96 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 97 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 98 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION) TABLE 99 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 100 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 101 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 102 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 103 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021-2028 (USD MILLION) TABLE 104 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 105 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 106 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 107 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 108 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022) TABLE 109 REGENERATIVE MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION) TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 113 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 114 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 115 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 116 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 117 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 118 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 119 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 120 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 123 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 124 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 125 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 129 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 130 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 131 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 134 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 135 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 136 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 137 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 138 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 139 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 140 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 141 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 144 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 145 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 146 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 149 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 150 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 151 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 154 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 155 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 156 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 159 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 160 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 161 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 165 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 166 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 167 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 170 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 171 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 172 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 175 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 176 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 177 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 180 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 181 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 182 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 185 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 186 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 187 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 190 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 191 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 192 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 195 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 196 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 197 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 201 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 202 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 203 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 206 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 207 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 208 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021-2028 (USD MILLION) TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 211 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 212 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 213 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 216 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 217 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 218 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021-2028 (USD MILLION) TABLE 221 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY TABLE 222 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) TABLE 223 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 224 REGENERATIVE MEDICINE MARKET: STRATEGIES ADOPTED BY KEY PLAYERS TABLE 225 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION TABLE 226 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS TABLE 227 REGENERATIVE MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS TABLE 228 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS TABLE 229 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS TABLE 230 REGENERATIVE MEDICINE MARKET: PRODUCT APPROVALS/LAUNCHES, JANUARY 2020 TO DECEMBER 2023 TABLE 231 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2020 TO DECEMBER 2023 TABLE 232 REGENERATIVE MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2020 TO DECEMBER 2023 TABLE 233 NOVARTIS AG: COMPANY OVERVIEW TABLE 234 BIOGEN INC.: COMPANY OVERVIEW TABLE 235 GILEAD SCIENCES, INC.: COMPANY OVERVIEW TABLE 236 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW TABLE 237 AMGEN, INC.: COMPANY OVERVIEW TABLE 238 SMITH+NEPHEW: COMPANY OVERVIEW TABLE 239 MEDIPOST CO., LTD.: COMPANY OVERVIEW TABLE 240 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW TABLE 241 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW TABLE 242 CORESTEM, INC.: COMPANY OVERVIEW TABLE 243 VERICEL CORPORATION: COMPANY OVERVIEW TABLE 244 MIMEDX GROUP, INC.: COMPANY OVERVIEW TABLE 245 ORGANOGENESIS INC.: COMPANY OVERVIEW TABLE 246 MEDTRONIC: COMPANY OVERVIEW TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW TABLE 248 ORTHOCELL LTD.: COMPANY OVERVIEW TABLE 249 MESOBLAST LTD.: COMPANY OVERVIEW TABLE 250 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW TABLE 251 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW TABLE 252 TEGOSCIENCE: COMPANY OVERVIEW TABLE 253 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW TABLE 254 BLUEBIRD BIO, INC.: COMPANY OVERVIEW TABLE 255 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW TABLE 256 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW TABLE 257 ASPECT BIOSYSTEMS: COMPANY OVERVIEW TABLE 258 ATHERSYS, INC.: COMPANY OVERVIEW
FIGURE 1 RESEARCH DESIGN FIGURE 2 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: REGENERATIVE MEDICINE MARKET, 2022 FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 FIGURE 5 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2022 FIGURE 6 PRODUCT-BASED REVENUE ANALYSIS, 2022 FIGURE 7 VALIDATION FROM PRIMARY EXPERTS FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH FIGURE 9 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET FIGURE 11 DATA TRIANGULATION METHODOLOGY FIGURE 12 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) FIGURE 13 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) FIGURE 14 GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET FIGURE 15 FOCUS ON PERSONALISED MEDICINE TO DRIVE MARKET GROWTH FIGURE 16 CELL THERAPY TO COMMAND LARGEST SHARE OF NORTH AMERICAN REGENERATIVE MEDICINE MARKET FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD FIGURE 18 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 19 PERCENTAGE OF FDA APPROVALS FOR PERSONALIZED MEDICINE PRODUCTS (2018-2022) FIGURE 20 REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES FIGURE 21 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET FIGURE 22 VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET FIGURE 23 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS FIGURE 24 KEY STEPS IN GENE THERAPY FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS FIGURE 26 KEY BUYING CRITERIA FOR END USERS FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020-2022 FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS (2020-2022) FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) FIGURE 32 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX, 2022 FIGURE 33 REGENERATIVE MEDICINE MARKET: START-UP/SME EVALUATION MATRIX, 2022 FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022) FIGURE 35 BIOGEN INC.: COMPANY SNAPSHOT (2022) FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022) FIGURE 37 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022) FIGURE 38 AMGEN, INC.: COMPANY SNAPSHOT (2022) FIGURE 39 SMITH+NEPHEW: COMPANY SNAPSHOT (2022) FIGURE 40 MEDIPOST CO., LTD.: COMPANY SNAPSHOT FIGURE 41 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2022) FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022) FIGURE 43 CORESTEM, INC.: COMPANY SNAPSHOT (2021) FIGURE 44 VERICEL CORPORATION: COMPANY SNAPSHOT (2022) FIGURE 45 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022) FIGURE 46 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022) FIGURE 47 MEDTRONIC: COMPANY SNAPSHOT (2022) FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
